SPR-965

N/A

Report date: 2023/01/14 19:28:05
NME

Base Information

Drug NameSPR-965
Drug Alias NameSPR-965
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase beta inhibitorsMammalian target of Rapamycin (mTORC1) inhibitorsmTOR Complex 2 inhibitors
TargetsPhosphatidylinositol 3 kinase betaMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSphaera PharmaYurui Pharmaceutical Technology (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYurui Pharmaceutical Technology (Shanghai) Co LtdSphaera Pharma
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A